For an animated presentation of ProCord, please click here.
ProCord - Spinal Cord Injury treatment
ProCord is an autologous activated macrophage therapy, for the
treatment of patients with acute complete spinal cord injury.
Following injury, a type of white blood cell, called
a macrophage, is quickly mobilized, and starts to remove cell
debris. These macrophages then start to secrete growth factors
that promote a controlled inflammatory reaction, the initial
phase of the wound healing process. While this process normally
occurs in most tissues, including peripheral nerves, it does
not occur in the central nervous system (CNS), including the
spinal cord. Preclinical studies led by Prof. Michal Schwartz
of the Weizmann Institute of Science have shown that specially-treated
macrophages promote recovery from spinal cord injury (SCI).
Based on these findings, Proneuron is developing ProCord as
a clinical product to treat spinal cord injury patients. ProCord
consists of macrophages isolated from the patient's own blood,
co-incubated with the patient's skin in a proprietary process
and then injected directly into the patient's injured spinal
cord. For the Scientific articles please
Human activated macrophage
Proneuron is currently engaged in an international, multicenter,
randomized-control, Phase II trial of ProCord as a treatment for spinal cord injuries.